Screening For Down's Syndrome. The Role Of Intact Hcg and Free Subunit Measurement

References

• Merkatz I R, Nitowsky H M, Macri J N, Johnson W E. An association between low maternal serum alpha fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 1984; 148: 886–94
   PubMed Web of Science ®Google Scholar
• Cuckle H S, Wald N T, Lindenbaum R H. Maternal serum alpha fetoprotein measurement: A screening test for Down syndrome. Lancet 1984; i: 926–9
   Google Scholar
• Spencer K, Carpenter P. Screening for Down's syndrome using serum alpha fetoproteins retrospective study indicating caution. BMJ 1985; 290: 1940–3
   PubMed Web of Science ®Google Scholar
• Cuckle H S, Wald N T, Thomson S G. Estimating a woman's risk of having a pregnancy associ ated with Down's syndrome using her age and serum alpha fetoprotein level. Br J Obstet Gy naecol 1987; 94: 387–402
   PubMedGoogle Scholar
• Reynolds T M, Penney M D. The mathematical basis of multivariate risk screening with special reference to screening for Down's syndrome associated pregnancy. Ann Clin Biochem 1990; 27: 452–8
   PubMed Web of Science ®Google Scholar
• Canick J A, Knight G J, Palomaki G E, et al. Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome. Br J Obstet Gynaecol 1988; 95: 330–3
   PubMedGoogle Scholar
• Wald N T, Cuckle H S, Densem T W, et al. Mater nal serum unconjugated oestriol as an antenatal screening test for Down's syndrome. Br J Obstet Gynaecol 1988; 95: 334–41
   PubMedGoogle Scholar
• Macri J N, Kasturi R V, Krantz D A, et al. Maternal serum Down syndrome screening: unconju gated estriol is not useful. Am J Obstet Gynecol 1990; 162: 672–3
   PubMed Web of Science ®Google Scholar
• Macri J N, Krantz D A, Kasturi R V, Cook E J, Larsen J W. Measurement of unconjugated es triol by enzyme linked immunosorbent assay fails to show an association with Down syn drome. Am J Obstet Gynecol 1990; 162: 1634–5
   PubMed Web of Science ®Google Scholar
• Spencer K. Evaluation of an assay of the free beta subunit of choriogonadotropin and its potential value in screening for Down's syn drome. Clin Chem 1991; 37: 809–14
   PubMed Web of Science ®Google Scholar
• Spencer K, Coombes E J, Mallard A S, Milford Ward A. Free beta human choriogonadotropin in Down's syndrome screening: a multicentre study of its role compared with other biochemi cal markers. Ann Clin Biochem 1992; 29: 506–18
   PubMed Web of Science ®Google Scholar
• Crossley J A, Aitken D A, Connor J M. Second trimester unconjugated oestriol levels in mater nal serum from chromosomally abnormal preg nancies using an optimised assay. Prenat Diagn 1993; 13, In press
   Web of Science ®Google Scholar
• Macri J N, Kasruri R V, Cook E J, Krantz D A. Prenatal screening for Down's syndrome. BMJ 1991; 303: 468
   PubMedGoogle Scholar
• Reynolds T M, John R, Spencer K. Unconjugated estriol is not useful in Down's syndrome screening. Clin Chem 1993; 39, In press
   PubMed Web of Science ®Google Scholar
• Reynolds T M, John R. Comparison of assay kits for unconjugated estriol shows that expressing results as multiples of the median causes unac ceptable variation in calculated risk factors for Down's syndrome. Clin Chem 1992; 38: 1888–93
   PubMed Web of Science ®Google Scholar
• Bartels I. Maternal levels of preg nancy specific beta 1 glycoprotein (SP1) are elevated in pregnancies affected by Down's syndrome. Hum Genet 1988; 80: 46–8
   PubMed Web of Science ®Google Scholar
• Wald N J, Cuckle H S, Densem J M. Maternal serum specific beta 1 glycoprotein (SP1) in pregnancies associated with Down's syn drome. Lancet 1989; ii: 450
   Google Scholar
• Knight G J, Palomaki G E, Haddow J E, et al. Maternal serum levels of the placental products hCG, hPL, SP1 and progesterone are elevated in cases of fetal Down syndrome. Am J Hum Genet 1989; 45: A263
   Google Scholar
• Petrocik E, Wassman R, Lee J, Kelly J C. Second trimester maternal serum pregnancy specific beta 1 glycoprotein (SP1) levels in normal and Down syndrome pregnancies. Am J Med Genet 1990; 37: 114–8
   PubMed Web of Science ®Google Scholar
• Bartels I, Thiele M, Bogart M H. Maternal serum hCG and SP1 in pregnancies with fetal aneu-ploidy. Am J Med Genet 1990; 37: 261–4
   PubMed Web of Science ®Google Scholar
• Spencer K. Pregnancy specific beta 1 glycopro tein in Down's syndrome screening: does it have any value?. Proceedings of the ACB Na tional Meeting 1991; 108
   Google Scholar
• Graham G W, Crossley J A, Aitken D A, Connor J M. Variation in the levels of pregnancy specific beta 1 glycoprotein in maternal serum from chromosomally abnormal pregnancies. Prenat Diagn 1992; 12: 505–12
   PubMed Web of Science ®Google Scholar
• Brock D JH, Barron L, Holloway S, et al. First trimester maternal serum biochemical indica tors in Down's syndrome. Prenat Diagn 1990; 10: 242–51
   Web of Science ®Google Scholar
• Check J H, Kosrow N, Vaze M, et al. Very high CA125 levels during early first trimester in three cases of spontaneous abortion with chromosomal abnormalities. Am J Obstet Gynecol 1990; 162: 674–5
   PubMed Web of Science ®Google Scholar
• Spencer K. Maternal serum CA125 is not a sec ond trimester marker for Down's syndrome. Ann Clin Biochem 1991; 28: 299–300
   PubMed Web of Science ®Google Scholar
• VanLith J MM, Mantingh A, Beekhuis J R, de-Bruijn H WA. Breed ASPM. First trimester CA125 and Down's syndrome. Br J Obstet Gy naecol 1991; 98: 493–4
   PubMedGoogle Scholar
• Hogdall C K, Hogdall E VS, Arends J, et al. CA125 as a maternal serum marker for Down's syndrome in the first and second trimesters. Prenat Diagn 1992; 12: 223–7
   PubMed Web of Science ®Google Scholar
• Grozdea J, Vergnes H, Martin J. Urea-resistant neutrophil alkaline phosphatase in mothers with trisomy 21 pregnancy. Lancet 1983; ii: 799
   Google Scholar
• Cuckle H S, Wald N J, Goodburn S F, et al. Measurement of activity of urea resistant neu trophil alkaline phosphatase as an antenatal screening test for Down's syndrome. BMJ 1990; 301: 1024–6
   PubMed Web of Science ®Google Scholar
• Ren S-G, Braunstein G D. Human chorionic go nadotropin. Seminars Reproduct Endocrinol 1992; 10: 95–105
   Google Scholar
• Birken S, Armstrong E G, Kolks M AG. Structure of the human chorionic gonadotropin beta subunit fragment from pregnancy urine. Endocrinology 1988; 123: 572–83
   PubMed Web of Science ®Google Scholar
• Nishimura R, Ide K, Utsonomiya T, et al. Frag mentation of the beta subunit of human cho rionic gonadotropin produced by choriocarci noma. Endocrinology 1988; 123: 420–5
   PubMed Web of Science ®Google Scholar
• Bidart J-M, Puisieux A, Troalen F, et al. Charac terization of cleavage product in the human chorionic gonadotropin beta subunit. Biochem Biophys Res Commun 1988; 154: 626–32
   PubMed Web of Science ®Google Scholar
• Cole L A, Kardana A. Discordant results in human chorionic gonadotropin assays. Clin Chem 1992; 38: 263–70
   PubMed Web of Science ®Google Scholar
• Kardana A, Cole L A. Polypeptide nicks cause erroneous results in assays of human chorionic gonadotropin free beta subunit. Clin Chem 1992; 38: 26–33
   PubMed Web of Science ®Google Scholar
• Bidart J-M, Troalen F, Lazar V, et al. Monoclo nal antibodies to the Free Beta subunit of human chorionic gonadotropin define three distinct antigenic domains and distinguish be tween Intact and Nicked molecules. Endocrino logy 1992; 131: 1832–40
   PubMed Web of Science ®Google Scholar
• Birkin S, Gawinowicz M A, Kardana A, Cole L A. The heterogeneity of Human Chorionic Gonadotropin (hCG).II. Characteristics and origin of nicks in hCG reference standards. En docrinology 1991; 129: 1551–8
   PubMed Web of Science ®Google Scholar
• Cole L A, Kardana A, Andrade-Gordon P. The heterogeneity of Human Chorionic Gonadotropin (hCG).III. The occurrence and biologi cal and immunological activities of nicked hCG. Endocrinology 1991; 129: 1559–67
   PubMed Web of Science ®Google Scholar
• Chard T, Lowings C, Kitau M J. Alpha fetopro tein and chorionic gonadotropin levels in rela tion to Down syndrome. Lancet 1984; ii: 750
   Google Scholar
• Bogart M H, Pandian M R, Jones O W. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnor malities. Prenat Diagn 1987; 7: 623–30
   PubMed Web of Science ®Google Scholar
• Wald N T, Cuckle H S, Densem J W, et al. Mater nal serum screening for Down's syndrome in early pregnancy. BMJ 1988; 297: 883–7
   PubMed Web of Science ®Google Scholar
• Wald N J, Cuckle H S. Biochemical screening. Prenatal diagnosis and screening, D JH Brock, C Rodeck. Churchill Living stone, Edinburgh 1992
   Google Scholar
• Bogart M H, Golbus M S, Sorg N D, Jones O W. Human chorionic gonadotropin levels in preg nancies with aneuploid fetuses. Prenat Diagn 1989; 9: 379–84
   PubMed Web of Science ®Google Scholar
• Ryall R G, Staples A J, Robertson E F, Pollard A C. Improved performance in a prenatal screening programme for Down's syndrome incorpora ting serum free hCG subunit analysis. Prenat Diagn 1992; 12: 251–61
   PubMed Web of Science ®Google Scholar
• Spencer K. Free alpha hCG in Down's syn drome. Am J Obstet Gynecol 1993; 165: 132–5
   Web of Science ®Google Scholar
• Macri J N, Kasturi R V, Krantz D A, et al. Mater nal serum Down syndrome screening: free beta protein is a more effective marker than human chorionic gonadotropin. Am J Obstet Gynecol 1990; 163: 1248–53
   PubMed Web of Science ®Google Scholar
• Spencer K, Macri J N. Early detection of Down's syndrome using free beta human choriogona dotropin. Ann Clin Biochem 1992; 29: 349–50
   PubMed Web of Science ®Google Scholar
• Macri J N, Spencer K, Anderson R. Dual analyte immunoassay in Neural Tube Defect and Down's syndrome screening. Ann Clin Biochem 1992; 29: 390–6
   PubMed Web of Science ®Google Scholar
• Spencer K, Macri J N, Anderson R V, et al. Dual analyte immunoassay in Neural Tube Defect and Down's Syndrome screening: Results of a multicentre clinical trial. Ann Clin Biochem 1993; 30, In press
   Web of Science ®Google Scholar
• Crossley J A, Aitken D A, Connor J M. Free beta hCG and prenatal screening for chromosome abnormalities. J Med Genet 1991; 28: 570
   Google Scholar
• Cuckle H S, Lilford R. Antenatal screening for Down's syndrome. BMJ 1992; 305: 1017
   PubMed Web of Science ®Google Scholar
• Knight G J, Cole L A. Measurement of choriogo nadotropin free beta subunit: an alternative to choriogonadotropin in screening for fetal Down's syndrome. Clin Chem 1991; 37: 779–82
   PubMed Web of Science ®Google Scholar
• Spencer K, Macri J N, Carpenter P, Anderson R, Krantz D A. Intact hCG stability in serum, liquid whole blood and dried whole blood filter paper spots and its impact on free beta hCG Down's syndrome screening. Clin Chem 1993; 39, In press
   Web of Science ®Google Scholar
• Macri J N, Spencer K, Anderson R, Cook E J. Free beta chorionic gonadotropin: A cross reactivity study of two immunometric assays used in pre natal maternal serum screening for Down syn drome. Ann Clin Biochem 1993; 30: 94–8
   PubMed Web of Science ®Google Scholar
• Rotmensch S, Liberati M, Kardana A, et al. Pep tide heterogeneity of human chorionic gonado tropin (hCG) and its beta subunit in Down syn drome pregnancies. Am J Obstet Gynecol 1992; 166: 354
   Google Scholar
• Wald N J, Cuckle H S, Densem J W, Kennard A, Smith D. Maternal serum screening for Down's syndrome: the effect of routine ultrasound determination of gestational age and adjust ment for maternal weight. Br J Obstet Gynaecol 1992; 99: 144–9
   PubMedGoogle Scholar
• Reynolds T M, Penney M D, Hughes H, John R. The effect of weight correction on risk calcula tions for Down's syndrome screening. Ann Clin Biochem 1991; 28: 245–9
   PubMed Web of Science ®Google Scholar
• Wald N, Cuckle H, Wu T, George L. Maternal serum unconjugated oestriol and human cho rionic gonadotrophin levels in twin pregnan cies; implications for screening for Down's syn drome. Br J Obstet Gynaecol 1991; 98: 905–8
   PubMedGoogle Scholar
• Cuckle H S, Wald N J, Densem J W, et al. The effect of smoking in pregnancy on maternal serum alpha fetoprotein, unconjugated oes triol, human chorionic gonadotrophin, proges terone and dehydroepiandrosterone sulphate levels. Br J Obstet Gynaecol 1990; 97: 272–6
   PubMedGoogle Scholar
• Kline J, Stein Z, Susser M, Warburton D. New insights into epidemiology of chromosome dis orders: their relevance to the prevention of Down's syndrome. Frontiers in knowledge in Mental retardation. Vol II, Bio chemical Aspects, P Milter. University Park Press, Baltimore, 131–41
   Google Scholar
• Shino P H, Klebanoff M A, Berendes H W. Con genital malformations and maternal smoking during pregnancy. Teratology 1986; 34: 65–71
   PubMedGoogle Scholar
• Hook E B, Cross P L. Cigarette smoking and Down syndrome. Am J Hum Genet 1985; 37: 1216–24
   PubMed Web of Science ®Google Scholar
• Christianson R E, Torfs C P. Maternal smoking and Down syndrome. Am J Hum Genet 1988; 43: 545–6
   PubMed Web of Science ®Google Scholar
• Hook E B, Cross P K. Maternal cigarette smok ing, Down syndrome in live births and infant race. Am J Hum Genet 1988; 42: 482–9
   PubMed Web of Science ®Google Scholar
• Cuckle H S, Alberman E, Wald N J, Royston P, Knight G. Maternal smoking habits and Down's syndrome. Prenat Diagn 1990; 10: 561–7
   PubMed Web of Science ®Google Scholar
• Hook E B, Regal R R. Conceptus viability, mal formation and suspect mutagens or teratogens in humans. The Yule-Simpson paradox and im plications for inferences of causality in studies of mutagenicity or teratogenicity limited to human live births. Teratology 1991; 43: 53–9
   PubMedGoogle Scholar
• MuUer F, Boue A. A single chorionic gonado tropin assay for maternal serum screening for Down's syndrome. Prenat Diagn 1990; 10: 389–98
   PubMed Web of Science ®Google Scholar
• Bogart M H, Jones O W, Felder R A, et al. Pros pective evaluation of maternal serum human chorionic gonadotropin levels in 3428 pregnan cies. Am J Obstet Gynecol 1991; 165: 663–7
   PubMed Web of Science ®Google Scholar
• Wald N J, Kennard A, Densem J W, et al. Ante natal maternal serum screening for Down's syndrome: results of a demonstration project. BMJ 1992; 305: 391–4
   PubMed Web of Science ®Google Scholar
• Haddow J E, Palomaki G E, Knight G J, et al. Pre natal screening for Down's syndrome with use of maternal serum markers. N Engl J Med 1992; 327: 588–93
   PubMed Web of Science ®Google Scholar
• Phillips O P, Elias S, Shulman L P, et al. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha fetoprotein, hCG and unconjugated oestriol: A prospective 2 year study. Obstet Gynecol 1992; 80: 353–8
   PubMed Web of Science ®Google Scholar
• Spencer K, Carpenter P. Preliminary results of a prospective study of Down's syndrome screening using Free Beta hCG. Clin Chem 1992; 38: 957
   Google Scholar
• Cuckle H S, Wald N J, Barkai G, et al. First tri mester biochemical screening for Down syn drome. Lancet 1988; ii: 851–2
   Google Scholar
• Johnson A, Cowchock F S, Darby M, Wapner R, Jackson L G. First trimester maternal serum alpha fetoprotein and chorionic gonadotropin in aneuploid pregnancies. Prenat Diagn 1991; 11: 443–50
   PubMed Web of Science ®Google Scholar
• Crandall B F, Golbus M S, Goldberg J D, Matsu-moto M. First trimester maternal serum uncon jugated oestriol and alpha fetoprotein in fetal Down's syndrome. Prenat Diagn 1991; 11: 377–80
   PubMed Web of Science ®Google Scholar
• Nebiolo L, Ozturk M, Brambarti B, et al. First trimester maternal serum alpha fetoprotein and human chorionic gonadotropin screening for chromosome defects. Prenat Diagn 1990; 10: 575–81
   PubMed Web of Science ®Google Scholar
• Kratzner P G, Golbus M S, Monroe S E, Finkel-stein D E, Taylor R N. First trimester aneuploidy screening using serum human chorionic gona dotropin (hCG), Free alpha hCG and proges terone. Prenat Diagn 1991; 11: 751–65
   PubMed Web of Science ®Google Scholar
• VanLith J MM. First trimester maternal serum human chorionic gonadotrophin as a marker for fetal chromosomal disorders. Prenat Diagn 1992; 12: 495–504
   PubMed Web of Science ®Google Scholar
• Spencer K, Macri I N, Aitken D A, Connor J M. Free Beta hCG as first trimester marker for fetal trisomy. Lancet 1992; 339: 1480
   PubMed Web of Science ®Google Scholar
• Macri J N, Spencer K, Aitken D A, et al. First trimester free beta Down syndrome screening. Prenat Diagn 1993; 13, In press
   Web of Science ®Google Scholar
• Spencer K, Aitken D A, Muller F. Biochemical markers of Trisomy 21 in amniotic fluid. Clin Chem 1993; 39, In press
   Google Scholar
• Deville J L, Gaspard U, Reuter A M, Franchi-mont P, Lambotte R. Maternal serum levels of chorionic gonadotropin and its alpha and beta free subunits as a function of fetal sex. C R Soc Biol 1980; 174: 365–9
   PubMedGoogle Scholar
• Wolf G C, Byrn F W, McConnell T S, Khazaeli M B. Amniotic fluid levels of human chorionic gonadotropin and its alpha and beta subunits in second trimester chromosomally abnormal pregnancies. Prenat Diagn 1992; 12: 93–101
   PubMed Web of Science ®Google Scholar
• Spencer K, Wood P J, Anthony F W. Elevated levels of maternal serum inhibin immunoreac-tivity in second trimester pregnancies affected by Down's syndrome. Ann Clin Biochem 1993; 30: 219–20
   PubMed Web of Science ®Google Scholar
• VanLith J MM, Pratt J J, Beekhuis J R, Mantingh A. Second trimester maternal serum immu-noreactive inhibin as a marker for fetal Down's syndrome. Prenat Diagn 1992; 12: 801–6
   PubMed Web of Science ®Google Scholar
• Canick J A, Palomaki G E, Osathanondh R. Pre natal screening for trisomy 18 in the second trimester. Prenat Diagn 1990; 10: 546–8
   PubMed Web of Science ®Google Scholar
• Greenberg F, Schmidt D, Darnule A T, et al. Maternal serum alpha fetoprotein, human cho rionic gonadotrophin and unconjugated estriol levels in midtrimester trisomy 18 pregnancies. Am J Obstet Gynecol 1992; 166: 1388–92
   PubMed Web of Science ®Google Scholar
• Spencer K, Macri J N, Mallard A S, Coombes E J. Trisomy 18 screening using Free Beta hCG. Clin Chem 1993; 39, In press
   Google Scholar
• Staples A J, Robertson E F, Ranien E, Ryall R G, Haan E A. A maternal serum screen for Trisomy 18: An extension of maternal serum screening for Down syndrome. Am J Hum Genet 1991; 49: 1025–33
   PubMed Web of Science ®Google Scholar
• Laundon C, Spencer K, Macri J N, Buchanan P. Turner syndrome detection by MSAFP/Free Beta (hCG) screening. J Med Genet 1993; 30, In press
   Google Scholar
• Canick J A, Knight G J, Palomaki G E, Haddow J E. Second trimester levels of maternal serum unconjugated oestriol and human chorionic go nadotropin in pregnancies affected by fetal an-encephaly and open spina bifida. Prenat Diagn 1990; 10: 733–7
   PubMed Web of Science ®Google Scholar
• Cuckle H S, Densem J W, Wald N J, Gonen R, Perez R, David M, et al. The associ-hydatidiform mole in maternal serum screen- ation between unexplained second trimestering programmes for Down's syndrome. Br J maternal serum hCG elevation and pregnancy Obstet Gynaecol 1992; 99: 495–7
   PubMedGoogle Scholar
• Gonen R, Perez R, David M, et al. The association between unexplained second himester maternal serum hCG elevation and pregnancy complications. Obstet Gynecol 1992; 80: 83–6
   PubMed Web of Science ®Google Scholar